Replies to post #2432 on Spectrum Pharmaceutecals Inc (SPPI)

[antihama]

Rolontis, the "Show me" drug needs to prove itself. Here's my musings on sales potential from post 2408

I don't expect any significant revenue streams starting till 2022 unless Spectrum tells us differently. For kicks here's my revenue expectations
2019 - 3 Million
2020 - 20 Million
2021 - 40 Million
2022 - 50 Million
2023 - 60 Million

Please prove me wrong Spectrum and make those #s higher but the bottom line is you need to show us.

Looking back at those revenues I'm thinking I was too generous for this year, it should be zero revenue in 2019. Maybe I'm just jaded from the screw-up /delay of not having Rolontis on the market right now but they need to prove my expection wrong.

Regarding Qapzola, being a new entity, they'll have 5 yrs exclusivity in the market before generics kick in. I could see Qapzola possibly hitting that 200M mark in year 5 but then the generics will kick in. Considering that they'll probably need a specialized sales force (I think) to visit urologist offices, my feeling is they should finish the P3, submit the NDA, and licence it to a more specialized company that work w urologists. Ipsen comes to mind.